• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation.

作者信息

Portnoy Allison, Pedersen Kine, Trogstad Lill, Hansen Bo T, Feiring Berit, Laake Ida, Smith Megan A, Sy Stephen, Nygård Mari, Kim Jane J, Burger Emily A

机构信息

Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Boston, MA, USA.

Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.

出版信息

Prev Med. 2021 Sep;150:106688. doi: 10.1016/j.ypmed.2021.106688. Epub 2021 Jul 21.

DOI:10.1016/j.ypmed.2021.106688
PMID:34303489
Abstract
摘要

相似文献

1
Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation.基于当前经验数据和验证情况，评估挪威九价人乳头瘤病毒（HPV）疫苗的成本效益。
Prev Med. 2021 Sep;150:106688. doi: 10.1016/j.ypmed.2021.106688. Epub 2021 Jul 21.
2
Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.九价人乳头瘤病毒（HPV）疫苗的潜在成本效益。
Int J Cancer. 2014 May 1;134(9):2264-8. doi: 10.1002/ijc.28541. Epub 2013 Oct 31.
3
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.新加坡九价人乳头瘤病毒疫苗预防宫颈癌的成本效益分析。
Vaccine. 2021 Apr 15;39(16):2255-2263. doi: 10.1016/j.vaccine.2021.03.040. Epub 2021 Mar 18.
4
Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.选择最佳 HPV 疫苗：48 个有资格获得 Gavi 支持的国家中九价和二价 HPV 疫苗的健康影响和经济价值。
Int J Cancer. 2021 Feb 15;148(4):932-940. doi: 10.1002/ijc.33233. Epub 2020 Aug 11.
5
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.九价人乳头瘤病毒疫苗接种后宫颈癌个体残余风险的估计。
Hum Vaccin Immunother. 2018 Jul 3;14(7):1800-1806. doi: 10.1080/21645515.2018.1450125. Epub 2018 May 24.
6
Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.对于接种下一代九价人乳头瘤病毒（HPV）疫苗的女性，子宫颈癌筛查是否仍具有成本效益？四个发达国家的结果。
Int J Cancer. 2016 Dec 15;139(12):2771-2780. doi: 10.1002/ijc.30392.
7
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.澳大利亚人乳头瘤病毒初筛背景下新一代九价人乳头瘤病毒疫苗的成本效益：比较建模分析。
Lancet Public Health. 2016 Dec;1(2):e66-e75. doi: 10.1016/S2468-2667(16)30019-6. Epub 2016 Nov 29.
8
Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.在宫颈癌发病率高和筛查覆盖率低的情况下，HPV 疫苗接种的成本效益。
Vaccine. 2017 Nov 1;35(46):6329-6335. doi: 10.1016/j.vaccine.2017.08.083. Epub 2017 Sep 9.
9
Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis.加速宫颈癌消除策略的影响和成本效益：基于模型的分析。
Prev Med. 2021 Mar;144:106276. doi: 10.1016/j.ypmed.2020.106276. Epub 2021 Mar 4.
10
Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.针对 HPV 疫苗接种女性的宫颈癌筛查策略调整：分层指南的价值。
Eur J Cancer. 2018 Mar;91:68-75. doi: 10.1016/j.ejca.2017.12.018. Epub 2018 Jan 12.

引用本文的文献

1
Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands.荷兰青春期前接种九价与二价人乳头瘤病毒疫苗对健康和经济的预期影响
BMC Med. 2025 Jun 9;23(1):339. doi: 10.1186/s12916-025-04170-3.